CA-MAWI-DNA-TECHNOLOGIES
11.5.2021 15:02:10 CEST | Business Wire | Press release
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that MagBio Genomics has successfully developed an automated RNA purification method for iSWAB-RNA v2 on the Thermofisher KingFisher™ Flex platform with its HighPrep™ Total RNA Isolation Kit - iSWAB™.
Mawi DNA Technologies’ iSWAB-RNA v2 allows for non-invasive self collection, concentration, and stabilization of intact buccal cells and/or any mammalian cells collected with a swab or cytobrush. It enables up to four weeks of real-time ambient stabilization of total RNA from the point of collection to processing. The high-quality RNA extracted from stabilized iSWAB-RNA v2 samples is suitable for gene expression applications such as real-time quantitative PCR, reverse transcription PCR, microarrays, northern blot analysis, nuclease protection assays, cDNA library construction and RNA-seq.
“Collaborating with MagBio Genomics to optimize their HighPrep™ Total RNA Plus Kit-iSWAB™ for iSWAB-RNA v2 was a no-brainer for us, especially because it provides a great option for our high throughput end users like pharma and CROs,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies. “Partnerships with leaders in nucleic acid purification chemistries with a global presence, such as MagBio Genomics, are increasing worldwide access of our sample collection technologies, which results in better understanding of health and wellness at a global rather than at a regional level.” El-Fahmawi said that due to increased sample sizes in cohort genetic population studies, there is an increasing need for automated RNA purification solutions. The MagBio HighPrep Total RNA Plus Kit-iSWAB™ simplifies this research step, which can be labor-intensive.
“MagBio has successfully developed and optimized the HighPrep™ Total RNA Isolation Kit-iSWAB™ for extraction of total RNA from iSWAB-RNA v2 samples on Thermofisher KingFisher™ Flex Purification System,” said Dr. Mothomang Mlalazi-Oyinloye, Associate Scientific Director, MagBio Genomics. “This new method is being used by a major pharmaceutical company to process iSWAB-RNA v2 samples for elucidation of molecular mechanisms of cancer development. With this automated protocol, 96 samples can be run in less than one hour.” She added that the extracted RNA is of high purity and quality and is compatible with complex and sensitive assays. RNA yields up to 1ug per sample are obtained (Qubit RNA Broad Assay).
“We are expanding our automated methods library to include the most commonly used lab automation systems,” Dr. Mlalazi-Oyinloye said. “iSWAB-RNA v2 is the non-invasive sample collection alternative to venipuncture and tissue biopsy our fellow researchers have been looking for which maintains RNA integrity especially during long transit times. MagBio Genomics is all about making the next generation sequencing workflow better. We developed an automated method for simplifying RNA purification from iSWAB-RNA v2 samples using our HighPrep™ Total RNA Plus Kit-iSWAB™,” said Dr. Hyacinth Ntchobo, CEO, MagBio Genomics. He added that when used in combination, Mawi’s iSWAB-RNA v2 collection technology and MagBio Genomics’ purification chemistry provide an efficient workflow for high throughput purification of high-quality RNA for demanding downstream applications.
About MagBio Genomics Inc.
MagBio Genomics is a global company that develops and commercializes magnetic bead-based products for nucleic acid isolation including biomarkers as tools for liquid biopsy genomic research. The current focus encompasses products that cover the complete sample preparation for NGS; from allowing safeguarding integrity of bio-samples, efficient isolation of circulating biomarkers to target enrichment from biological samples. Products are applied to human genetic research including cancer genomic studies and non-invasive prenatal testing (NIPT).“WE SIMPLY MAKE NGS BETTER.” For more information, visit http://www.magbiogenomics.com .
About Mawi DNA Technologies
Mawi DNA Technologies has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, with robust DNA yield and low bacterial DNA content. Mawi DNA has established relationships with children’s hospitals for neonatal screening and has an extensive global network of international distributors to market and sell iSWAB products. For more information, visit http://www.mawidna.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005456/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 15:00:00 CEST | Press release
New end-to-end resilience and managed security offerings help organizations reduce security complexity, cut system downtime by up to 50%, and lower remediation costs by up to 40% by bringing devices, security technologies, expert services, and ecosystem partners together under a single operational model As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations
Tacton Launches Portfolio Performance Intelligence to Help Manufacturers Understand Why Products Win30.6.2026 15:00:00 CEST | Press release
New configuration-aware commercial intelligence capability connects customer requirements, configuration decisions, and business outcomes to optimize win rates, margin and product strategy. Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of Portfolio Performance Intelligence, a new analytics capability designed to help manufacturers understand why products win, where margin is created or lost, and which decisions consistently drive successful business outcomes. Manufacturers don't lack data. They lack the context needed to understand why products perform the way they do and why customers choose them. ERP systems show what was sold, CRM platforms track opportunities, and BI tools visualize trends. But when manufacturers try to understand which customer requirements drive demand, which configurations consistently win, or why margins vary across products, regions or segments, the answers are often unclear
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom